PCML
ROIV icon

Pavaki Capital Management LLC’s Roivant Sciences ROIV Stock Holding History

Pavaki Capital Management LLC’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-40,000
Closed -$868K – 160
2025
Q4 		$868K Buy
+40,000
New +$789K 0.34% 46

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Pavaki Capital Management LLC's ROIV Position: Q1 2026 in Review

Pavaki Capital Management LLC sold out of Roivant Sciences (ROIV) in Q1 2026, closing a stake of 40,000 shares — an estimated $868K sold.

Pavaki Capital Management LLC first reported a position in ROIV in Q4 2025 and held it in 1 quarter. The position peaked at $868K in Q4 2025. 441 funds tracked by Wall St. Rank hold ROIV as of Q1 2026.

  • Pavaki Capital Management LLC reported no remaining Roivant Sciences position as of Q1 2026 after selling out during the quarter.
  • Pavaki Capital Management LLC sold 40,000 Roivant Sciences shares in Q1 2026, an estimated $868K.
  • Pavaki Capital Management LLC first reported a position in Roivant Sciences in Q4 2025 and held it in 1 quarter.
  • Pavaki Capital Management LLC's Roivant Sciences position peaked at $868K in Q4 2025.
  • 441 funds tracked by Wall St. Rank held Roivant Sciences as of Q1 2026.

Based on Pavaki Capital Management LLC's 13F filing for Q1 2026, filed 7 Aug 2026.